Towards a Cannabinoid Hypothesis of Schizophrenia: Cognitive Impairments Due to Dysregulation of the Endogenous Cannabinoid System

Cognitive impairments during psychotic episodes are assumed to be caused not only by one single putative classical neurotransmitter dysfunction but also by an impaired equilibrium of the interaction between different neurobiological generators of cognitive processes. Herein, the perceptual abnormalities induced by psychotogenic agents play a major role as tools for the understanding of model psychoses. The recently discovered cannabinoid receptor system with its endogenous ligand anandamide can be regarded as an extremely relevant regulator system, a dysfunctionality of which may explain at least one subtype of endogenous psychoses. Neuropsychological results (three-dimensional inversion illusion) in delta 9-tetrahydrocannabinol-intoxicated normal volunteers exhibit strong similarities with data acquired from patients suffering from productive schizophrenic psychoses, regarding disturbances in internal regulation of perceptual processes. The relevance of this finding to a general cognitive dysfunction concept of schizophrenic psychosis is discussed.

[1]  V. Peralta,et al.  Influence of cannabis abuse on schizophrenic psychopathology , 1992, Acta psychiatrica Scandinavica.

[2]  S. Shukla,et al.  Cannabis psychosis and paranoid schizophrenia. , 1976, Archives of general psychiatry.

[3]  D. J. Spencr Cannabis induced psychosis. , 1970, The British journal of addiction to alcohol and other drugs.

[4]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[5]  M. Herkenham,et al.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[6]  D. W. Goodwin,et al.  Marihuana Use and Psychiatric Illness , 1972 .

[7]  L E Hollister,et al.  Health aspects of cannabis. , 1986, Pharmacological reviews.

[8]  P. Allebeck,et al.  Schizophrenia in users and nonusers of cannabis , 1989, Acta psychiatrica Scandinavica.

[9]  M. Herkenham,et al.  Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Lowinson,et al.  Marijuana's interaction with brain reward systems: Update 1991 , 1991, Pharmacology Biochemistry and Behavior.

[11]  J. Smith,et al.  Psychotic reactions following cannabis use in East Indians. , 1974, Archives of general psychiatry.

[12]  A. Robins,et al.  CANNABIS-ASSOCIATED PSYCHOSIS WITH HYPOMANIC FEATURES , 1982, The Lancet.

[13]  S. Cooper,et al.  The Clinical Correlates of Neurological Soft Signs in Chronic Schizophrenia , 1991, British Journal of Psychiatry.

[14]  S. Almog,et al.  Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. , 1993, Journal of medicinal chemistry.

[15]  R. Albertini,et al.  Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. , 1968, Lancet.

[16]  A. Howlett,et al.  Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.

[17]  J. Vanderhaeghen,et al.  Glutamatergic regulation of cannabinoid receptor gene expression in the caudate-putamen. , 1994, European journal of pharmacology.

[18]  K. Mine,et al.  Δ 9-Tetrahydrocannabinol facilitates striatal dopaminergic transmission , 1989, Pharmacology Biochemistry and Behavior.

[19]  K. Täschner Zur Psychopathologie und Differentialdiagnose sogenannter Cannabispsychosen , 1983 .

[20]  H. Emrich,et al.  A Three-Component-System Hypothesis of Psychosis , 1989, British Journal of Psychiatry.

[21]  J. Lieberman,et al.  A selective review of biological markers in schizophrenia. , 1991, Schizophrenia bulletin.

[22]  A. Ciaranello,et al.  Genetics of major psychiatric disorders. , 1991, Annual review of medicine.

[23]  Heinrichs Dw,et al.  Significance and meaning of neurological signs in schizophrenia. , 1988 .

[24]  H Thomas,et al.  Psychiatric Symptoms in Cannabis Users , 1993, British Journal of Psychiatry.

[25]  P. Seeman,et al.  Dopamine receptor pharmacology. , 1994, Trends in pharmacological sciences.

[26]  R. Mechoulam,et al.  Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .

[27]  T. Crow,et al.  Molecular pathology of schizophrenia: more than one disease process? , 1980, British medical journal.

[28]  D. Kupfer,et al.  A comment on the "amotivational syndrome" in marijuana smokers. , 1973, The American journal of psychiatry.

[29]  P. Woodruff,et al.  Aetiology of Schizophrenia , 1995 .